Overview

A Study of BL-B01D1 in Patients With Recurrent Glioblastoma

Status:
RECRUITING

Trial end date:
2026-10-01

Target enrollment:

Participant gender:

Summary

This is an open-label, multicenter, phase II study to evaluate the safety, efficacy, and pharmacokinetic characteristics of BL-B01D1 for Injection in patients with recurrent glioblastoma.

Phase:

PHASE2

Details

Lead Sponsor:

Sichuan Baili Pharmaceutical Co., Ltd.

Collaborator:

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Treatments:

Injections